The following report looks interesting, however the stock did only react a little. Is there a medical person who can interpret this better, especially concerning demand for such a product and the significant of such a report, coming from SAmerica, not from a well knowen study center. Fred
-- Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that well-known diabetes investigator Dr. Jaime Guevara- Aguirre of the Institute of Endocrinology, Metabolism and Reproduction in Quito, Ecuador has published an Oral-lyn(TM) research paper in the November/December 2004 edition (Volume 20, Issue 6) of Diabetes/Metabolism Research and Reviews (Copyright (C) 2004 John Wiley & Sons, Ltd.).
The paper is entitled Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oral-lyn) with subcutaneous (SC) insulin injection, a proof of concept study. The objective of the study was to evaluate the metabolic effect of Oral-lyn(TM), the Company's proprietary oral insulin spray formulation, at breakfast time in subjects with type 2 diabetes on multiple daily injections.
The results of the study demonstrated that Oral-lyn(TM) can be used as meal insulin in place of mealtime insulin injections in subjects with type 2 diabetes to regulate postprandial glucose levels.
"The importance of this paper cannot be emphasized enough," said Dr. Gerald Bernstein, Vice-President of Medical Affairs for Generex. "The concept of replacing mealtime insulin injections with a needle-free system thereby opening the door for better compliance may change the landscape of the treatment of diabetes."
The study was co-authored by Marco Guevara and Jeannette Saavedra (both of the Institute of Endocrinology, Metabolism and Reproduction), Marko Mihic (of St. Joseph's Hospital, University of Toronto, Toronto, Canada) and Pankaj Modi (of Generex).
|
